Omnihealth Practice

ONCOLOGY

Bridging towards allogeneic stem-cell transplant with the early use of novel therapies in the relapsed/refractory acute lymphoblastic leukemia setting

12 Aug 2021

Improving the management of advanced and late-line gists with dual action tyrosine kinase inhibitors

06 Aug 2021

Drugging the undruggable KRAS with sotorasib, the first-in-class KRAS^G12C inhibitor for advanced NSCLC

09 Jul 2021

Interview with the Expert: Dr. Peter YM Woo - Glioblastoma Multiforme (GBM) Treatment with Combination of TTFields and Chemotherapy: When and Where to Implement TTFields in the Clinical Setting?

07 Jun 2021

Expanding first-line renal cell carcinoma treatment to patients with favorable risks: A sharing of local cases

01 Jun 2021

The PROfound promise of genomics in mCRPC management

12 May 2021

Real-world analysis found ixazomib triple therapy effective in the management of relapsed/refractory multiple myeloma

28 Feb 2021

Clinical challenges and considerations in managing HR+/HER2- advanced breast cancer in the post-CDK inhibitor setting

31 Dec 2020

A case of patient with advanced hepatocellular carcinoma - maximizing clinical benefits through timely switching away from failing regimen

31 Dec 2020

Denosumab as a well-tolerated and effective bone targeting treatment option for multiple myeloma patients with osteolytic lesions

31 Dec 2020

Improving the management of advanced and late-line gists with dual action tyrosine kinase inhibitors

Gastrointestinal stromal tumors (GISTs) are the most common primary mesenchymal tumors of the gastrointestinal (GI) tract with an estimated incidence and prevalence of 14.5 and 129 per million population, respectively, in the United States.¹ While imatinib is the standard treatment for locally advan

06 Aug 2021

Dr. Margret von Mehren

Chief, Division of Sarcoma Medical Oncology
Physician Director, Clinical Trials Office
Associate Director, Clinical Research
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center,
United States

Interview with the Expert: Dr. Peter YM Woo - Glioblastoma Multiforme (GBM) Treatment with Combination of TTFields and Chemotherapy: When and Where to Implement TTFields in the Clinical Setting?

Currently, the standard of care for patients with glioblastoma multiforme (GBM) consists of surgical resection or biopsy followed by adjuvant concurrent chemo-radiotherapy (CCRT) with temozolomide.¹ To further improve the clinical course of GBM patients, tumor-treating fields (TTFields) were intr

07 Jun 2021

Dr. Peter YM Woo

Specialist in Neurosurgery

NCCN 2021

March 18-20, 2021 |
Virtual

Drugging the undruggable KRAS with sotorasib, the first-in-class KRAS^G12C inhibitor for advanced NSCLC

RESPIROLOGY ONCOLOGY

09 Jul 2021

Dr. Bob T. Li

Medical Oncologist,
Physician Ambassador to China and Asia-Pacific,
Bobst International Center
Co-Director, Thoracic Liquid Biopsy Program
Chief Scientific Officer, MSK Direct,
Memorial Sloan Kettering Cancer Center,
New York, United States

Bridging towards allogeneic stem-cell transplant with the early use of novel therapies in the relapsed/refractory acute lymphoblastic leukemia setting

Complete remission (CR) is a prerequisite to allogenic stem-cell transplant (allo-SCT) which remains to be the only curative option in adult with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).¹ However, conventional cytotoxic chemotherapies can only achieve CR in 40-50% of adult ALL pat

12 Aug 2021

Prof. Tse, Wai-Choi Eric

Clinical Professor,
Department of Medicine,
Li Ka Shing Faculty of Medicine,
The University of Hong Kong

Nivolumab as the first immunotherapy gained FDA accelerated approval for patients with previously untreated advanced gastric cancers

Accounted for 3.8% of all new cancer cases, gastric cancer (GC) was the sixth commonest cancer in Hong Kong in 2018.¹While chemotherapy remains as the standard of care for advance GC or gastroesophageal junction cancer (GEJC), most chemotherapy regimens fail to provide substantial survival benefits

29 Jun 2021

CROSS trial: 10-year persistent survival benefits with neoadjuvant chemoradiotherapy plus surgery in esophageal cancer

When managing patients with esophageal cancer, surgery alone remains a mainstream treatment for long but its isolated use is still subjected to many limitations.¹ Gradually, these limitations give rise to a multimodality therapeutic approach that leverages the strengths of different treatments to be

29 Jun 2021

ONCOLOGY

Potential risk factors for developing nerve damage after cancer treatment

12 May 2021

Expanding first-line renal cell carcinoma treatment to patients with favorable risks: A sharing of local cases

Renal cell carcinoma (RCC) is the most prevalent type of kidney malignancy, accounting for 90% of all cases.¹ Characterized by susceptibility to both immunotherapeutic and anti-angiogenic approaches, RCC can be treated with a combination of tyrosine kinase inhibitors (TKIs) and immune checkpoint inh

01 Jun 2021

Dr. So, Tsz-Him

Clinical Assistant Professor,
Department of Clinical Oncology,
Li Ka Shing Faculty of Medicine,
The University of Hong Kong